文献速递慢阻肺

脂成纤维细胞来源胞外囊泡通过恢复肺泡2型细胞减轻慢阻肺

Extracellular vesicle cargo from lipofibroblasts mitigates chronic obstructive pulmonary disease by alveolar type 2 cell restoration.
PubMed 文献 · Am J Respir Crit Care Med · 2026-01-01

研究探讨脂成纤维细胞来源胞外囊泡(LipoFB-EVs)对慢阻肺的治疗潜力。体外实验显示LipoFB-EVs可减轻肺上皮细胞衰老和炎症、抑制肌成纤维细胞分化并恢复AT2细胞功能,小鼠模型中也改善了气道炎症、重塑、阻塞、细胞衰老和肺气肿。

要点

  • LipoFB-EVs可减轻肺上皮细胞衰老和炎症反应。
  • LipoFB-EVs抑制TGF-β诱导的肌成纤维细胞分化。
  • LipoFB-EVs恢复AT2细胞活力、集落形成和增殖能力。

核心结论

  • LipoFB-EVs具有作为慢阻肺新型再生疗法的治疗潜力。

研究设计与样本

  • 体外用二甲双胍或罗格列酮诱导肺成纤维细胞转化为LipoFBs,超速离心分离EVs进行分析。
  • 在短期和长期香烟烟雾暴露的小鼠慢阻肺模型中给予LipoFB-EVs。

主要发现

  • LipoFB-EVs通过降低活性氧水平和调节DNA损伤应答通路减轻肺上皮细胞衰老和炎症。
  • LipoFB-EVs抑制TGF-β诱导的肌成纤维细胞分化,抗纤维化效果超过常规抗纤维化药物。
  • LipoFB-EVs增强AT2细胞活力、集落形成能力和增殖,恢复受损的AT2干细胞。
  • LipoFB-EVs含L型氨基酸转运体1,介导氨基酸摄取尤其是亮氨酸转运,参与恢复AT2细胞功能障碍。
  • 小鼠模型中LipoFB-EVs显著改善香烟烟雾诱导的气道炎症、重塑、阻塞、细胞衰老和肺泡肺气肿。

临床怎么用

  • LipoFB-EVs可能作为慢阻肺再生治疗的新方向,但尚需临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Emerging research highlights cellular abnormalities in chronic obstructive pulmonary disease (COPD), focusing on alveolar type 2 (AT2) cells, which are key to lung tissue repair and normal cellular differentiation. Lipofibroblasts (LipoFBs), stromal fibroblasts containing lipid droplets, are closely associated with AT2 cells and support their function. OBJECTIVES: We present a comprehensive investigation into the therapeutic potential of extracellular vesicles (EVs) derived from LipoFBs (LipoFB-EVs) in COPD treatment. METHODS: LipoFBs were induced from lung fibroblasts using Metformin or Rosiglitazone in vitro, and their EVs were isolated via ultracentrifugation for analysis. MAIN RESULTS: They effectively mitigate key COPD pathologies such as cellular senescence and inflammatory responses in lung epithelial cells. This is achieved by reducing reactive oxygen species (ROS) levels and modulating DNA damage response pathways. Moreover, LipoFB-EVs demonstrate anti-fibrotic properties by inhibiting TGF-β-induced myofibroblast differentiation, surpassing conventional anti-fibrotic drugs. They also aid in restoring impaired AT2 stem cells, which are crucial for lung homeostasis, by enhancing their viability, colony-forming ability, and proliferation. Furthermore, we identify the presence of L-type amino acid transporter 1 within LipoFB-EVs, which mediates amino acid uptake, particularly leucine transport, and contributes to the restoration of AT2 cell dysfunction. Importantly, the administration of LipoFB-EVs in murine models of COPD resulted in significant improvements in airway inflammation, remodeling, obstruction, cellular senescence, and alveolar emphysema induced by both short- and long-term CS exposure. CONCLUSIONS: Our findings highlight the therapeutic potential of LipoFB-EVs as a novel regenerative therapy for COPD, offering promising avenues for future clinical interventions.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Fujimoto S, Hirano Y, Kawajiri K, et al. Extracellular vesicle cargo from lipofibroblasts mitigates chronic obstructive pulmonary disease by alveolar type 2 cell restoration. Am J Respir Crit Care Med. 2026. PMID: 41738201. doi:10.1093/ajrccm/aamag025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。